Skip to main content

Table 4 Characteristics of patients in the independent test set 2

From: Genomic transcriptional profiling identifies a candidate blood biomarker signature for the diagnosis of septicemic melioidosis

Sample ID Age (years) Sex Bacterial isolation Antibiotherapy before blood collection Underlying diseases Survival
Other sepsis (n = 7)       
   I027* 64 Female E. coli † Fortum, ceftriaxone UGIB Non-survivor
   I028‡ 81 Female Corynebacterium spp. Ceftriaxone, fortum, clindamycin T2D Survivor
   I029‡ 74 Female S. aureus Fortum, ceftriaxone, tazocin Asthma, emphysema, ARF Survivor
   I031* 48 Male Enterococcus spp. Fortum Urinary tract infection Survivor
   I032* 54 Female E. faecium Fortum, tazocin T2D, respiratory failure Non-survivor
   I033* 63 Female E. coli † Tazocin, ceftriaxone, fortum T2D, ovarian cancer Survivor
   I034* 43 Male A. hydrophila † Tazocin - Survivor
Septicemic melioidosis (n = 8)       
   M031* 49 Male B. pseudomallei Fortum, bactrim, tazocin T2D Non-survivor
   M032* 54 Male B. pseudomallei Fortum, doxycycline, sulperazone T2D Non-survivor
   M033* 44 Male B. pseudomallei Fortum, sulperazone, bactrim, ciprofloxacin T2D Survivor
   M034* 40 Female B. pseudomallei Fortum, bactrim, ceftazidime, ceftriaxone T2D Survivor
   M035* 56 Male B. pseudomallei Ceftriaxone, ceftazidime, fortum COPD, T2D Non-survivor
   M036* 41 Female B. pseudomallei Ceftriaxone, ceftazidime T2D Non-survivor
   M037* 42 Female B. pseudomallei Bactrim, fortum, cloxacillin T2D Survivor
   M038* 49 Female B. pseudomallei Ceftriaxone, fortum, ceftazidime, levofloxacin - Non-survivor
  1. *Community-acquired septicemia; ‡hospital-acquired septicemia. †Positive by two sets of blood cultures. ARF, acute renal failure; COPD, chronic obstructive pulmonary disease; T2D, type 2 diabetes; UGIB, upper gastrointestinal bleeding.
Back to article page

Genome Biology

ISSN: 1474-760X

Contact us